Hospitals | April 13, 2026
Orbis India Partners Meet 2026 focuses on sustainable, climate-resilient eye care
Green Vision Centres cut emissions, expand community coverage as partners align on resilient eye health systems
Green Vision Centres cut emissions, expand community coverage as partners align on resilient eye health systems
The study is a global, randomized, double-blind, placebo-controlled trial testing GLM101 for phosphomannomutase 2 congenital disorder of glycosylation
The FDA clearance of Zeto New Wave marks the company’s third cleared device, alongside Zeto WR19 and Zeto ONE
The device aims to bring precision neuroscience into clinical trials, accelerating drug development
The dual expansion simplifies transcriptomics workflows by combining faster regional turnaround with easier sample logistics
Nature Medicine study delivers strongest real-world evidence yet for India’s indigenous rotavirus vaccine under UIP
Drugmaker taps 1 million retail touchpoints, quick commerce and modern trade to expand ingredient-led skincare franchise
Both ordinary resolutions sail through with over 99.6% votes in favour, strengthening leadership continuity at the drugmaker
API maker begins circulation of second and final call money notice for partly paid-up rights shares, completing the last leg of its 2024 fundraising cycle
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
